peoplePerson
Igor Puzanov
Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.
Melanoma oncologist who led early oncolytic virus combination trials and directs Roswell Park's phase 1 programme.
Role
Director, Early Phase Clinical Trials Program; Chief, Melanoma Section
Institution
Specialisms
MelanomaOncolytic virusesImmune-related toxicity
Profiles
| Title | Journal | Year |
|---|---|---|
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma | Journal of Clinical Oncology | 2016 |
Pages like this
not linked directly; found by shared links- PairingOncolytic virus + PD-1 blockade
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
- PersonKevin Harrington
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
- TrialKEYNOTE-006
Shares Ipilimumab, Melanoma.
- CompanyReplimune
Shares Oncolytic viruses, Melanoma.
- PersonAlexander Eggermont
Shares Ipilimumab, Melanoma.
- TechnologyIntratumoural gene electrotransfer (IL-12 plasmid)
Shares Oncolytic viruses, Melanoma.
- InstitutionUniversity Hospital Zurich / Comprehensive Cancer Center Zurich
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
- IdeaOncolytic viruses that make interleukin-12 only inside the tumour
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.